HER2 Negative Breast Cancer

WATCH: @YAbdouMD, of @UNC_Lineberger, discusses updates in the treatment of patients with HR-positive, HER2-negative breast cancer. #bcsm #oncology https://t.co/bm3XbNunzN (@OncLive)

Selection and sequencing of CDK4/6 inhibitors in metastatic HR+/HER2- breast cancer hinge on the maturation of data in the first-line setting and beyond, and need to account for patient concerns and preferences. @drsarahsam @DanaFarber #bcsm #oncology https://t.co/SxrWSHh8F9 (@OncLive)

During this event, Claudine Isaacs, MD, discussed the role of #elacestrant for patients with ER+, HER2-negative breast cancer. #bcsm | @LombardiCancer @claudine_isaacs https://t.co/HV86Y63CKw (@TargetedOnc)

The EMA's Committee for Medicinal Products for Human Use has adopted a positive opinion regarding sacituzumab govitecan monotherapy in select patients with unresectable or metastatic HR–positive, HER2-negative breast cancer. @JavierCortesMD #bcsm https://t.co/jU6u7chlOD (@OncLive)

Elizabeth A. Mittendorf, MD, PhD, discussed the TROPiCS-02 trial, which evaluated sacituzumab govitecan in HR–positive, HER2-negative breast cancer. #bcsm | @EMittendorfMD @DanaFarber https://t.co/KFZ6dleKn1 (@TargetedOnc)

Single-agent sacituzumab govitecan has received a positive opinion from @EMA_News regarding its use in unresectable or metastatic HR–positive, HER2-negative breast cancer based on data from the phase 3 TROPiCS-02 study. @JavierCortesMD #bcsm https://t.co/urqbkNoe0v (@OncLive)

New📰published: AMEERA-3: Randomized Phase II Study of Amcenestrant Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. @stolaney1 and colleagues. https://t.co/QqL6DtT4C7 (@DFCI_BreastOnc)

Gedatolisib + palbociclib & letrozole produced durable responses w/ comparable safety to that observed w/ palbociclib & letrozole alone in treatment-naïve patients withER-positive, HER2-negative advanced breast cancer @hoperugo @UCSFCancer #bcsm https://t.co/Hpc5ZFF5GJ (@OncLive)

Gedatolisib + palbociclib & letrozole produced durable responses w/ comparable safety to that observed w/ palbociclib & letrozole alone in treatment-naïve patients withER-positive, HER2-negative advanced breast cancer @hoperugo @UCSFCancer #bcsm https://t.co/D5Xk9qw1X0 (@OncLive)

all the metastatic hormone positive her2 negative breast cancers don’t benefit from CDK4/6 inhibitors in front line! Speaker: Barbara Pistilli #florencebreast23 @OncoAlert @acampsmalea @ChelainG @MartaPerachino @FatjonaKrajaMD @FrancicaPaola (@Dr_m_garousi)

In this interview by @VJOncology I share a summary of the findings presented at #ASCO23 about the academic #NeoRhea trial - neoadjuvant palbociclib + ET for early ER+/HER2-neg #breastcancer https://t.co/2KtmdkZGmo (@ElisaAgostinett)

It’s really a shame if @AnthemBCBS is not approving ribociclib for 1st line metastatic ER+HER2- breast cancer. (@FelipeBatalini)

WATCH: @stolaney1, of @DanaFarber, discusses key data from a final overall survival analysis of the phase 3 TROPiCS-02 trial in hormone receptor–positive, HER2-negative breast cancer. #bcsm https://t.co/aFwiSRwpDr (@OncLive)

Out now! Days 1 - 5 #ASCO23 👉🏻 @OncoAlert newsletter! Compelling for 🙋🏼‍♀️: SONIA - comp safety, efficacy & $$ burden for pts comparing 1L vs 2L use of CDK4/6i in HR+/HER2-neg adv #breastcancer. @StoverLab rec personalized approach, w/ key ?’s https://t.co/o9xdNnEcuM #bcsm https://t.co/9k6LL0CGqQ (@JaniceTNBCmets)

Women are being reclassified from HER2-neg #breastcancer & getting life-changing care. “With >60% of patients being HER2-low, this is opening up a lot of treatment options.” @maryam_lustberg #ASCO23 https://t.co/hy0kSSdrVu @SmilowCancer @YaleMed @YNHH @YaleBreast (@YaleCancer)

Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC). @stolaney1 Summary: https://t.co/EhtJ4vYzX0 #ASCO23 #bcsm (@paspears88)

Breast Cancer Research: Final results of TROPiCS-02 reported at #ASCO23. Data shows antibody-drug conjugate offers significant survival benefit for patients with HR-positive/HER2-negative metastatic breast cancer Read more ➡️ https://t.co/mBMz5ZnZox CC: @DFCI_BreastOnc @STolaney1 (@DanaFarberNews)

Nan Chen, MD, Assistant Professor @UChicagoMed presents cool data on the outcomes from using combinatorial treatment of #Pembrolizumab and #Mifepristone in HER2-ve #breastcancer patients. @UCCancerCenter @UChicagoBreast @UChicagoHemOnc @RitaNandaMD (@UCCancerCenter)

In this video, Adam Brufsky, MD, PhD, FACP, discusses palbociclib as a treatment option for patients with ER-positive, HER2-negative, advanced breast cancer. #bcsm | @UPMCHillmanCC @breastoncdoc @UPMCnews https://t.co/hl2rtyvCfz (@TargetedOnc)

Presented at #ASCO23 very important data from the #SOFT trial to increase our understanding of the biology of hormone receptor-positive/HER2-negative #BreastCancer in premenopausal women: congratulations @LoiSher @etop_ibcsg et all! @OncoAlert (@matteolambe)

Magistral lecture on the optimal duration of adjuvant ET in HR+/HER2- breast cancer by @MichaelGnant #ASCO23 👉Small but long term risk of recurrence ✂️Duration should be tailored based on the baseline risk (and tolerability) 💊Adherence is essential 🚨Carry-over effect (@antoniomarraMD)

Adjuvant Ribociclib And Endocrine Therapy In Patients With HR+/HER2 Negative Early Breast Cancer: Phase III NATALEE Trial by Dr. @gandhi_shipra of @RoswellPark https://t.co/vM9OYxvLni @DipeshUpretyMD @samsara_medico #ASCO23 #bcsm (@BTFCancerNews)

The addition of ribociclib to endocrine therapy extended invasive DFS for patients with hormone receptor-positive, HER2-negative early-stage breast cancer #ASCO23 @UCLAJCCC @MDAndersonNews @NovartisCancer @DrDebuTripathy #Kisqali #NATALEE https://t.co/je2JJdsf0t (@HemOncToday)

Lerociclib/Fulvestrant May Reduce Risk of Disease Progression in Advanced HR-Positive/HER2-Negative Breast Cancer https://t.co/TWzsHInxAr @ASCO #ASCO23 @glopesMD (@GlopesMd)

Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative eBC: Evidence and Controversies Increasing adjuvant treatment options in HER2-neg eBC are causing confusion. This topic is discussed in this excellent review @OncJournal @OncoAlert #breastcancer via @dr_yakupergun (@efrenbolivar)

Guideline Update Provides New Testing & Tx Recx for Pts w/ ER-Positive, HER2-Negative Met Breast Cancer w/ ESR1 Mutations [May 17-18, 2023] @ASCO Daily News - https://t.co/3ZVrEkQEN5 @DrHBurstein et al. @JCO_ASCO https://t.co/68e7D0CSgU #bcsm #PrecisionMedicine #LiquidBiopsy (@mtmdphd)

Can we predict HER2-low status using #HER2DX ERBB2 mRNA within HER2-negative breast cancer? Yes!! # ESMOBreast2023 ⁦@myESMO⁩ Next step is to test its value following T-DXd…working on it with ⁦@ScaltritiLab⁩ ⁦@esther_sanfeliu⁩ ⁦@fara_bm⁩ (@prat_aleix)

⁦@myESMO⁩ ⁦@MOliveira_MD⁩ presents results of ⁦@_SOLTI⁩ TOTHER3 trial Part B in HER2- breast cancer!! 30% ORR!! increase in CelTIL! #ESMOBreast2023 (@prat_aleix)

⁦@MOliveira_MD⁩ presents the ongoing VALENTINE neoadj trial in HR+/HER2- breast cancer! ⁦@_SOLTI⁩ #ESMOBreast2023 ⁦@myESMO⁩ (@prat_aleix)

Ribolaris trial in early stage HR+/HER2- breast cancer is recruiting very fast and is more important than ever now that we know that NATALEE trial is “positive”! @_SOLTI @GroupeUnicancer #ESMOBreast23 Poll below 👇 @OncoAlert (@prat_aleix)

Excellent paper. My guess: ER 'low' will persist as a clinically important breast cancer subgroup long after HER2 'low' returns to the "HER2 negative" fold. (@DrHBurstein)

HER2-low breast cancer had better survival outcomes compared to HER2 negative breast cancer in patients with early stage breast cancer https://t.co/O9gw4gnaOl (@MLPOncoData)

Watch Dr. Jennifer Litton discuss treatment recommendations and supporting research on use of endocrine therapy and CDK4/6 inhibitors for both metastatic and high-risk, early HR positive/HER2 negative breast cancer. https://t.co/b2WPpFRNbp @MDEdgeTweets @JenniferLitton #EndCancer (@MDAndersonNews)

New📰in Current Treatment Options in Oncology from Dr. Erica Mayers and Dr. Jamie Brett discussing new developments in systemic management for high-risk early-stage hormone-receptor-positive, HER2-negative breast cancer. @elmayermd #breastcancer 👉https://t.co/kJMnlxuaxX (@DFCI_BreastOnc)

...grade II invasive ductal carcinoma with lobular features (52 mm), ER8, HER2 negative. I can only imagine how you felt when you were forced to retire, but I honestly think you will do the world of good for the breast cancer community by the fundraising you've done, & by... (@MarlaStromberg)

.@ClaraRFarley1 beautifully presents @MDAndersonNews study on factors predicting 4 or more positive nodes in cN0 HR+/Her2- breast cancer. Important data as we try to better predict nodal burden which can impact systemic therapy decisions #ASBrS23 @ASBrS (@puneetsinghmd)

@DrJudyBoughey's treatnent strategy summary from the #ASBrS23 great debate re: neoadjuvant endocrine therapy in women with ER+/Her2- breast cancer (@throckad)

Novel endocrine therapies: What is next in HR+/HER2- breast cancer? - Just out in CTR. Perfectly on time ahead of the upcoming session on this topic at ESMO Breast 😉hope you’ll enjoy the reading. See you in Berlin⁦⁦🇩🇪 ⁦⁦⁦@myESMO⁩ https://t.co/L03NLktBDv (@CarmenCriscit)

Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer? An excellent review👇 https://t.co/WEdbZlHexv (@dr_yakupergun)

Meet Central California Hematology Oncology Conference faculty, Dr. @gandhi_shipra of @RoswellPark! Dr. Gandhi will present "Updates in Hormone Receptor-Positive and HER-2 Negative Breast Cancers." REGISTER: https://t.co/6bqVmdACkm #BTFCentralCA #JuneEvents #2023Events #CME (@btfoundation)

Dr Erica Mayer (@elmayermd) is a co-investigator on SERENA-6 (NCT04964934), an ongoing randomized, double-blind, phase III trial of camizestrant + CDK4/6i in ESR1-mutant HR+/HER2-negative advanced breast cancer during first-line treatment. Trial protocol: https://t.co/bIeMClWmjx (@DFCI_BreastOnc)

also, stay tuned for this mini-oral from my group! 3MO - HER2 expression and early response to patritumab deruxtecan (HER3-DXd) in early-stage hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC): a correlative analysis from SOLTI-TOT-HER3 trial (ID 48) @_SOLTI… https://t.co/rfUtZabNh8 (@prat_aleix)